Giving Covid-19, Together Flu Vaccines Are Safe, Study Finds


[ad_1]

CDC and WHO now say no need to separate vaccines

Concurrent reception of Covid-19 and seasonal influenza vaccines has been shown to be both safe and effective, with little change in immune response reported in a sub-study of the phase III trial of the NVX- vaccine. CoV2373 Covid-19 (Novavax).

Co-administration of NVX-CoV2373 vaccine and influenza vaccine was associated with only a slight reduction in the effectiveness of the Covid-19 vaccine, and no serious adverse events were reported in participants in the study receiving both injections at the same time.

The substudy, published online in the journal Lancet Respiratory Medicine, is among the first to examine the safety, immunogenicity and efficacy of co-administration of a Covid-19 vaccine and a seasonal influenza vaccine.

CDC recently approved the co-administration of Covid-19 and non-Covid vaccines, noting in a recent directive that “Covid-19 vaccines can be administered regardless of the timing of other vaccines.”

In previous guidelines, however, CDC officials have recommended a two-week interval between the administration of a Covid-19 vaccine and the flu. Health agencies in other countries, including the United Kingdom, have also advised against co-administration of vaccines in the first few months of the availability of the Covid-19 vaccine.

The The World Health Organization weighed in last month, concluding that the co-administration of any vaccine against Covid-19 and inactivated seasonal influenza is acceptable, “given that the known risk of serious illness for adults infected with the influenza virus or SARS-CoV-2 is substantial “.

Write in Respiratory Lancet Medication, researcher Seth Toback, MD, of Novavax, Gaithersburg, Md., and colleagues noted that the results of the sub-study provide “much needed information to help guide decision-making on national immunization policy. the important issue of the concomitant use of Covid-19 vaccines with influenza vaccines. ”

In accompaniement remark, immunologists Daniel Altmann, PhD, and Rosemary Boyton, PhD, of Imperial College London, wrote that the initial warning about co-administering the vaccine was understandable.

“When rolling out new vaccines at such a rapid pace while trying to maintain a high bar for safety, a high degree of caution was warranted in the uncharted territory of vaccine co-administration,” they wrote.

They added that lessons learned from Covid-19 vaccination programs challenge “long-standing but poorly proven assumptions” about the risks associated with co-administration of vaccines, including the theory that the immune system could be overloaded by exposure to concurrent vaccines.

Altmann and Boyton wrote that the hypothesis, widely known as “vaccine interference,” “has always been confusing to basic immunologists accustomed to thinking that a person’s immune repertoire has the capacity to generate billions of dollars. B cell receptor sequences (each of these triggers the production of specific antibodies.) ‘

The authors of the comments concluded that the development of the Covid-19 vaccine has “supercharged the whole of vaccinology, giving the confidence to test new protocols and protect against various pathogens, even if that means administering the different vaccines at the same time.” time “. The recently published sub-study looked at 431 of Phase III study 2019nCoV-302 participants (n = 15,187) randomized to receive NVX-CoV2373 vaccine (n = 217) or placebo (n = 214) co-administered with seasonal influenza vaccine. Compared to the overall study population, participants in the substudy tended to be younger, more racially diverse, and have fewer comorbidities.

The primary endpoints of the study included the safety, immunogenicity, and efficacy of NVX-CoV2373 vaccine when administered with seasonal influenza vaccine. Reactogenicity was analyzed in all participants who received at least one dose of the Covid-19 vaccine or placebo and whose data were collected for reactogenicity.

Reactogenicity events, including injection site tenderness, fatigue, and muscle pain, were found to be more common in the co-administration group than in the NVX-CoV2373 alone group (sensitivity, 64.9% vs. 53 , 3%; fatigue, 27.7% vs. 19.4%; muscle pain 28.3% vs. 21.4%, but serious adverse events were rare with no significant difference reported between the two groups No episode of anaphylaxis or death was reported during the substudy.

Co-administration did not result in any change in the immune response to the influenza vaccine, although a slight reduction in antibody responses to the NVX-CoV2373 vaccine was noted. The efficacy of NVX-CoV2373 vaccine in the substudy in adult participants

“This substudy is the first to show the safety, immunogenicity and efficacy profile of a Covid-19 vaccine when co-administered with a seasonal influenza vaccine,” the researchers wrote. . “These data do not show any early safety concerns with the concomitant administration of NVX-CoV2373 with an influenza vaccine. The immunogenicity of the influenza vaccine was preserved with concomitant administration, although a modest decrease in the immunogenicity of the NVX-CoV2373 vaccine was found. ”

Toback and colleagues concluded that “future clinical trials and post-approval studies of Covid-19 vaccines should include safety and immunogenicity data for co-administration with current adult and pediatric vaccines. Further research on concomitant Covid-19 vaccination and influenza vaccines is needed, particularly in people over 65, to help guide national vaccination policy on this important issue. ”

  1. Concurrent reception of Covid-19 and seasonal influenza vaccines has been shown to be both safe and effective, with little change in immune response reported in a sub-study of the phase III trial of the NVX- vaccine. CoV2373 Covid-19.

  2. The substudy is among the first to examine the safety, immunogenicity and efficacy of co-administration of a Covid-19 vaccine and seasonal influenza vaccines.

Salynn Boyles, Contributing Writer, BreakingMED â„¢

This study was funded by Novavax. Toback and other researchers have claimed to be employees of Novavax. Commentators Altmann and Boyton said they received compensation for consultations with OxfordImmunoTec.

Cat ID: 125

Subject ID: 79 125 730 933.125.30 31 926 192 561 653 927 150 151 928 924 925 934

[ad_2]

Comments are closed.